1. Generics Bulletin

Formycon’s Keytruda Biosimilar Enters Phase I Clinical Trial

Phase III Study In NSCLC Patients Is Expected To Begin Shortly

 
• By Urtė Fultinavičiūtė

One of the self-proclaimed frontrunners in the pembrolizumab biosimilar race, Formycon, has initiated the first clinical trial for its FYB206 candidate. Meanwhile, Celltrion submits a Phase III trial application to the FDA, expecting “limitless” sales potential for its CT-P51 version.

Formycon company logo
• Source: Shutterstock

Formycon has started the clinical development program for its FYB206 candidate, a proposed biosimilar rival to the world’s best-selling drug Keytruda (pembrolizumab).

The firm has welcomed the first patient in its Phase I clinical trial, titled Dahlia, which will compare the pharmacokinetics, safety, and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.